Q1 2025 10X Genomics Inc Earnings Call Transcript
Key Points
- 10x Genomics Inc (TXG) reported total revenue of $155 million for Q1 2025, with strong performance in consumables indicating robust core demand.
- The company settled worldwide patent litigation with Vizgenerate on favorable terms, receiving a $26 million settlement.
- Increased usage of products driven by price elasticity and new applications supports long-term growth potential.
- Recent product launches, including GEM-X technology and Visium HD, are resonating well with customers, enhancing technology leadership.
- Strong cash position and cost-saving measures, including an 8% workforce reduction, are being implemented to navigate current challenges.
- First quarter revenue, excluding settlement-related revenue, was $138 million, down 2% year-over-year, primarily due to a significant decrease in instrument revenue.
- The macro environment, particularly US academic and government research funding, is creating deep uncertainty and impacting customer purchasing behavior.
- 10x Genomics Inc (TXG) withdrew its full-year revenue guidance due to unpredictable customer purchasing behavior and reduced visibility.
- Instrument revenue was down 42% year-over-year, with significant declines in both Chromium and spatial instrument sales.
- The company is exposed to ongoing uncertainty in the US academic and government research funding environment, which supports 40% to 50% of its revenue.
Ladies and gentlemen, thank you so much for standing by, and welcome to 10x Genomics first quarter 2025 earnings conference call. Please note that this call is being recorded. (Operator Instructions)
I'd now like to hand the call over to Cassie Corneau, Senior Director, Investor Relations. You may now begin.
Thank you, and good afternoon, everyone. Earlier today, 10x Genomics released financial results for the first quarter ended March 31, 2025. If you have not received this news release or would like to be added to the company's distribution list, please send an e-mail to [email protected]. An archived webcast of this call will be available on the Investor tab of the company's website, 10xgenomics.com, for at least 45 days following this call.
Before we begin, I'd like to remind you that management will make statements during this call that are forward-looking statements within the meaning of federal securities laws. These statements involve material risks and
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
